Screener
Matinas BioPharma MTNB Q1 2026 Annual earnings
Reported May 8, 2026 · After market close
EPS-$0.30Beat by $1.02
Revenue estimate$25.0K
EPS estimate-$1.32
Next report
Nov 12, 2026 (in 2 months)Revenue estimate$25.0K
EPS estimate-$1.32
Versus estimates
Diluted EPS
Q2 2026-$0.21Beat by $1.11
Q1 2026-$0.30Beat by $1.02
Q4 2025-$0.24Beat by $1.08Q3 2025-$0.40Q2 2025-$1.03Q1 2025-$1.68Miss by $0.90FAQ
- When did Matinas BioPharma report Q1 2026 earnings?
- Matinas BioPharma (MTNB) reported Q1 2026 earnings on May 8, 2026 after market close.
- What were Matinas BioPharma's Q1 2026 revenue and EPS?
- Matinas BioPharma reported eps of $-0.30 for Q1 2026.
- Did Matinas BioPharma beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-1.32 by $1.02.
- How did Matinas BioPharma's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 82.1% from $-1.68.
- Where can I find Matinas BioPharma's Q1 2026 SEC filings?
- You can read the 10-K periodic report (0001493152-26-014132) directly on SEC EDGAR. The filing index links above go to sec.gov.
